Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Ulcerative Colitis

In brief

•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.

Key facts

Study ID

NCT05610956

Run by

Tanta University

People needed

60

Starts

2023-01-01

Expected to finish

2026-12-01

Last updated by the study team

2025-07-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.

You may not qualify if…

• Other inflammatory bowel diseases (CD).
• History of serious hypersensitivity to empagliflozin or any component of the formulation.
• Patients on dialysis.
• Severe renal impairment (eGFR <20 ml/minute/1.73m2) .
• Chronic urinary tract infection.
• Chronic genital infection.

Where it is running

• Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital. — Tanta, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.